While there is pharmaceutical interest in targeting NaCT as a potential treatment for insulin resistance and non-alcoholic steatohepatitis [19, 34, 35], one must take into consideration the potential risks highlighted by human [23–26, 36] and /or rodent data, mainly epilepsy, developmental delays, and bone and tooth disorders. The gene discussed is SLC13A2; the disease is metabolic dysfunction-associated steatohepatitis.